Blood test may predict chemo side effects in leukemia patients

NCT ID NCT07254312

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 24, 2026 · Updated 15 times

Summary

This study is for adults with acute myeloid leukemia (AML) who are in remission after treatment with a combination of venetoclax and a hypomethylating agent. The goal is to see if the amount of venetoclax in the blood is linked to severe low white blood cell counts (neutropenia). By understanding this, doctors hope to adjust doses to reduce side effects and keep patients on therapy longer. The study will enroll 14 participants and measure venetoclax levels using a special blood test.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fondazione IRCCS Policlinico San Matteo, SC Oncologia
RECRUITING

Pavia, Pavia, 27100, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

AML (ACUTE MYELOGENOUS LEUKEMIA)